CN1198618C - 1－[4－(5－氰基吲哚－3－基)丁基]－4－(2－氨基甲酰基－苯并呋喃－5－基)－哌嗪及其生理学上可接受的盐的新用途 - Google Patents

1－[4－(5－氰基吲哚－3－基)丁基]－4－(2－氨基甲酰基－苯并呋喃－5－基)－哌嗪及其生理学上可接受的盐的新用途 Download PDF

Info

Publication number
CN1198618C
CN1198618C CNB008081352A CN00808135A CN1198618C CN 1198618 C CN1198618 C CN 1198618C CN B008081352 A CNB008081352 A CN B008081352A CN 00808135 A CN00808135 A CN 00808135A CN 1198618 C CN1198618 C CN 1198618C
Authority
CN
China
Prior art keywords
benzofuran
butyl
carbamoyl
cyanindol
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008081352A
Other languages
English (en)
Chinese (zh)
Other versions
CN1361692A (zh
Inventor
G·巴托斯茨克
C·塞弗里德
C·范阿姆斯特达姆
H·贝特彻尔
E·赛德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1198618(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1361692A publication Critical patent/CN1361692A/zh
Application granted granted Critical
Publication of CN1198618C publication Critical patent/CN1198618C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB008081352A 1999-05-27 2000-05-16 1－[4－(5－氰基吲哚－3－基)丁基]－4－(2－氨基甲酰基－苯并呋喃－5－基)－哌嗪及其生理学上可接受的盐的新用途 Expired - Fee Related CN1198618C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99109295.8 1999-05-27
EP99109295 1999-05-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN200910113677A Division CN101869565A (zh) 1999-05-27 2000-05-16 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰基-苯并呋喃-5-基)-哌嗪及其生理学上可接受的盐的新用途
CNA2005100544177A Division CN1679577A (zh) 1999-05-27 2000-05-16 1－[4－（5－氰基吲哚－3－基）丁基]－4－（2－氨基甲酰基－苯并呋喃－5－基）－哌嗪及其生理学上可接受的盐的新用途

Publications (2)

Publication Number Publication Date
CN1361692A CN1361692A (zh) 2002-07-31
CN1198618C true CN1198618C (zh) 2005-04-27

Family

ID=8238153

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB008081352A Expired - Fee Related CN1198618C (zh) 1999-05-27 2000-05-16 1－[4－(5－氰基吲哚－3－基)丁基]－4－(2－氨基甲酰基－苯并呋喃－5－基)－哌嗪及其生理学上可接受的盐的新用途
CNA2005100544177A Pending CN1679577A (zh) 1999-05-27 2000-05-16 1－[4－（5－氰基吲哚－3－基）丁基]－4－（2－氨基甲酰基－苯并呋喃－5－基）－哌嗪及其生理学上可接受的盐的新用途
CN200910113677A Pending CN101869565A (zh) 1999-05-27 2000-05-16 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰基-苯并呋喃-5-基)-哌嗪及其生理学上可接受的盐的新用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA2005100544177A Pending CN1679577A (zh) 1999-05-27 2000-05-16 1－[4－（5－氰基吲哚－3－基）丁基]－4－（2－氨基甲酰基－苯并呋喃－5－基）－哌嗪及其生理学上可接受的盐的新用途
CN200910113677A Pending CN101869565A (zh) 1999-05-27 2000-05-16 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰基-苯并呋喃-5-基)-哌嗪及其生理学上可接受的盐的新用途

Country Status (31)

Country Link
US (4) US6900212B1 (OSRAM)
EP (3) EP1410800B1 (OSRAM)
JP (2) JP4884588B2 (OSRAM)
KR (1) KR100683367B1 (OSRAM)
CN (3) CN1198618C (OSRAM)
AR (1) AR024112A1 (OSRAM)
AT (3) ATE438399T1 (OSRAM)
AU (1) AU771778B2 (OSRAM)
BR (1) BR0010948A (OSRAM)
CA (3) CA2372668C (OSRAM)
CY (2) CY1105750T1 (OSRAM)
CZ (1) CZ295623B6 (OSRAM)
DE (3) DE60009697T2 (OSRAM)
DK (3) DK1410800T3 (OSRAM)
ES (3) ES2271707T3 (OSRAM)
HK (1) HK1048444B (OSRAM)
HU (1) HU229059B1 (OSRAM)
IL (2) IL146707A0 (OSRAM)
MX (1) MXPA01012172A (OSRAM)
MY (1) MY135627A (OSRAM)
NO (2) NO322120B1 (OSRAM)
PL (3) PL200490B1 (OSRAM)
PT (3) PT1185272E (OSRAM)
RU (1) RU2237477C2 (OSRAM)
SI (2) SI1410800T1 (OSRAM)
SK (1) SK287851B6 (OSRAM)
TR (1) TR200103361T2 (OSRAM)
TW (1) TW518218B (OSRAM)
UA (1) UA74337C2 (OSRAM)
WO (1) WO2000072832A2 (OSRAM)
ZA (1) ZA200110485B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
US20040192730A1 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
US7893261B2 (en) 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
AU2007266890B2 (en) 2006-05-30 2011-02-17 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as DGAT1 inhibitors
CA2707660A1 (en) 2007-12-20 2009-07-02 Astrazeneca Ab Carbamoyl compounds as dgat1 inhibitors 190
MX2011014018A (es) 2009-06-19 2012-02-22 Astrazeneca Ab Pirazincarboxamidas como inhibidores de dgati.
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
EP2688884A1 (en) 2011-03-20 2014-01-29 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
EP2861586A4 (en) 2012-06-13 2015-11-11 Apotex Inc FORMS OF VILAZODONE AND METHODS OF PREPARATION THEREOF
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
EP3598971B1 (en) 2013-01-22 2024-03-20 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
EP3297619B1 (en) * 2015-05-22 2022-07-06 Vistagen Therapeutics, Inc. Therapeutic uses of l-4-chlorokynurenine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1291660A3 (en) * 2001-09-11 2003-05-28 Koyo Seiko Co., Ltd. Magnetic pulser ring, magnetizing device and method, and bearing unit having a magnetic pulser ring
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Also Published As

Publication number Publication date
CA2694866A1 (en) 2000-12-07
SI1410800T1 (sl) 2007-02-28
CA2372668A1 (en) 2000-12-07
EP1736158A2 (en) 2006-12-27
AR024112A1 (es) 2002-09-04
UA74337C2 (uk) 2005-12-15
US20100063062A1 (en) 2010-03-11
SK287851B6 (sk) 2012-01-04
NO20015746D0 (no) 2001-11-26
SK16462001A3 (sk) 2002-02-05
US7642261B2 (en) 2010-01-05
NO324230B1 (no) 2007-09-10
PT1410800E (pt) 2007-01-31
TW518218B (en) 2003-01-21
EP1410800A1 (en) 2004-04-21
ES2271707T3 (es) 2007-04-16
US7371756B2 (en) 2008-05-13
DE60042710D1 (de) 2009-09-17
DE60009697T2 (de) 2005-04-14
DE60009697D1 (de) 2004-05-13
EP1736158B1 (en) 2009-08-05
PT1185272E (pt) 2004-08-31
CN1679577A (zh) 2005-10-12
NO20061562L (no) 2001-11-26
JP4884588B2 (ja) 2012-02-29
IL146707A (en) 2007-06-03
DK1185272T3 (da) 2004-08-09
US20080119484A1 (en) 2008-05-22
CY1105750T1 (el) 2010-12-22
ATE438399T1 (de) 2009-08-15
CA2615271C (en) 2011-02-15
JP2011148799A (ja) 2011-08-04
HU229059B1 (en) 2013-07-29
JP2003500441A (ja) 2003-01-07
DE60030338T2 (de) 2007-08-16
AU5066300A (en) 2000-12-18
TR200103361T2 (tr) 2002-05-21
DE60030338D1 (de) 2006-10-05
CZ295623B6 (cs) 2005-09-14
WO2000072832A2 (en) 2000-12-07
PL352373A1 (en) 2003-08-25
NO322120B1 (no) 2006-08-14
ZA200110485B (en) 2003-06-30
HK1048444B (zh) 2005-12-09
DK1736158T3 (da) 2009-11-02
CZ20014226A3 (cs) 2002-03-13
MY135627A (en) 2008-05-30
AU771778B2 (en) 2004-04-01
PL199650B1 (pl) 2008-10-31
ATE337008T1 (de) 2006-09-15
HUP0201275A3 (en) 2004-04-28
SI1185272T1 (en) 2004-12-31
RU2237477C2 (ru) 2004-10-10
BR0010948A (pt) 2002-04-23
DK1410800T3 (da) 2006-12-27
CN101869565A (zh) 2010-10-27
CA2372668C (en) 2009-11-03
EP1410800B1 (en) 2006-08-23
HUP0201275A2 (en) 2002-08-28
NO20015746L (no) 2001-11-26
PT1736158E (pt) 2009-11-11
IL146707A0 (en) 2002-07-25
HK1048444A1 (en) 2003-04-04
KR100683367B1 (ko) 2007-02-15
US20050113386A1 (en) 2005-05-26
US6900212B1 (en) 2005-05-31
KR20020008847A (ko) 2002-01-31
ATE263564T1 (de) 2004-04-15
CA2615271A1 (en) 2000-12-07
MXPA01012172A (es) 2002-07-22
CY1109472T1 (el) 2012-05-23
EP1736158A3 (en) 2007-01-03
EP1185272A2 (en) 2002-03-13
ES2219342T3 (es) 2004-12-01
ES2330774T3 (es) 2009-12-15
WO2000072832A3 (en) 2001-12-20
EP1185272B1 (en) 2004-04-07
PL200490B1 (pl) 2009-01-30
PL199516B1 (pl) 2008-09-30
CN1361692A (zh) 2002-07-31

Similar Documents

Publication Publication Date Title
CN1198618C (zh) 1－[4－(5－氰基吲哚－3－基)丁基]－4－(2－氨基甲酰基－苯并呋喃－5－基)－哌嗪及其生理学上可接受的盐的新用途
JP2003500441A5 (OSRAM)
JPWO2019181854A1 (ja) てんかん治療剤
JP5436419B2 (ja) 精神障害の治療方法および治療用医薬組成物
US20120077825A1 (en) Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
HK1145439A (en) Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
Grzelewska-Rzymowska et al. Rupatadine: a novel second-generation antihistamine
CN114980874A (zh) 肌痛性脑脊髓炎/慢性疲劳症候群治疗剂
KR20100022956A (ko) 급성 조증 치료용 카르바모일-시클로헥산

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050427

Termination date: 20140516